Stocklytics Platform
Asset logo for symbol FGEN
FibroGen
FGEN67
$0.40arrow_drop_up15.12%$0.05
Penny Stock
Asset logo for symbol FGEN
FGEN67

$0.40

arrow_drop_up15.12%

Performance History

Chart placeholder
Key Stats
Open$0.35
Prev. Close$0.35
EPS-1.23
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$40.30M
PE Ratio-
LOWHIGH
Day Range0.34
0.42
52 Week Range0.28
2.93
Ratios
Revenue-
EPS-1.23

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

About FibroGen (FGEN)

FibroGen Inc (FGEN) is a biopharmaceutical company that focuses on the discovery, development, and commercialization of therapeutics for the treatment of serious and life-threatening conditions. The company is primarily focused on fibrosis and anemia, with its lead product candidate being roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) activity. Roxadustat is currently in Phase 3 clinical development for the treatment of anemia associated with chronic kidney disease (CKD) and myelodysplastic syndromes (MDS), and Phase 2 clinical development for the treatment of chemotherapy-induced anemia.
FibroGen Inc's stock price history has shown significant volatility over the past few years. The stock reached its all-time high of $76.64 in August 2018, but has since experienced a decline. As of [insert date], the stock is trading at $56.23. This represents a [insert percentage] decrease from its all-time high. The stock has a 52-week range of [insert range], indicating the extent of price fluctuations.
Sector
Healthcare
Industry
Biotechnology
CEO
Headquarters
San Francisco
Employees
592
Exchange
NASDAQ
add FibroGen  to watchlist

Keep an eye on FibroGen

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

Is FibroGen (FGEN) a growth stock?

FibroGen (FGEN) has shown an average price growth of -4.97% over the past three years. It has received a score of 3 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying FibroGen as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is FibroGen (FGEN) stock price performance year to date (YTD)?

As of the latest data, FibroGen (FGEN) has a year-to-date price change of -51.84%. Over the past month, the stock has experienced a price change of 1.16%. Over the last three months, the change has been 7.5%. Over the past six months, the figure is -66.67%. Looking at a longer horizon, the five-year price change stands at -99.11%.
help

What is FibroGen 's (FGEN) price per share?

The current price per share for FibroGen (FGEN) is $0.4. The stock has seen a price change of $0.05 recently, indicating a 15.13% change. This reflects the stock's recent market performance and investor sentiment.
help

What is the 52-week high and low for FibroGen (FGEN)?

For FibroGen (FGEN), the 52-week high is $2.93, which is 632.5% from the current price. The 52-week low is $0.29, the current price is 38.89% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

Is FibroGen (FGEN) a profitable company?

FibroGen (FGEN) has a net income of -$284.23M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 87.24% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -21.56% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , with a revenue growth rate of 4.99%, providing insight into the company's sales performance and growth. The gross profit is $128.9M. Operating income is noted at -$281.82M. Furthermore, the EBITDA is -$165.84M.
help

What is the market capitalization of FibroGen (FGEN)?

FibroGen (FGEN) has a market capitalization of $40.31M. The average daily trading volume is 0.4, indicating the stock's liquidity and investor engagement.

Take Your Investments to a Whole New Level